Publication Cover
The Women's Oncology Review
The Journal of Interdisciplinary Current Awareness
Volume 6, 2006 - Issue 3-4
1
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Chemoprevention for breast cancer: beyond tamoxifen

Vogel C, et al. Effects of Tamoxifen vs Raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–2741.

Pages 145-147 | Published online: 04 Dec 2011

References

  • Cuzick J, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361(9354): 296–300.
  • Freedman AN, et al. Estimates of the number of US women who could benefit from Tamoxifen for breast cancer chemoprevention. Journal of the National Cancer Institute 2003;95:526–532.
  • Port ER, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580–585.
  • Tchou J, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004;100:1800–1806.
  • Freedman AN, et al. Tamoxifen use for breast cancer chemoprevention among US women. European Journal of Cancer Supplement 2004;2:17–18.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.